Central nervous system myeloma: Pathogenesis, diagnostic challenges, and practical management strategies

IF 14.6 2区医学 Q1 HEMATOLOGY

HemaSphere Pub Date : 2025-10-13 DOI:10.1002/hem3.70213

Eirini Katodritou, Evangelos Terpos

引用次数: 0

Abstract

Central nervous system multiple myeloma (CNS-MM) is a rare and aggressive extramedullary manifestation of multiple myeloma, associated with poor prognosis and significant treatment challenges. Due to its rarity, data on incidence, risk factors, optimal therapeutic approaches, and long-term outcomes remain limited. This review aims to elucidate the current diagnostic and therapeutic challenges of CNS-MM and provide practical insights into real-life management strategies.

Abstract Image

查看原文本刊更多论文

中枢神经系统骨髓瘤：发病机制、诊断挑战和实际管理策略。

中枢神经系统多发性骨髓瘤（CNS-MM）是一种罕见的侵袭性髓外多发性骨髓瘤，预后差，治疗困难。由于其罕见性，关于发病率、危险因素、最佳治疗方法和长期结果的数据仍然有限。本综述旨在阐明当前CNS-MM的诊断和治疗挑战，并为现实生活中的管理策略提供实用的见解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

HemaSphere Medicine-Hematology

CiteScore

6.10

自引率

4.50%

发文量

2776

审稿时长

7 weeks

期刊介绍： HemaSphere, as a publication, is dedicated to disseminating the outcomes of profoundly pertinent basic, translational, and clinical research endeavors within the field of hematology. The journal actively seeks robust studies that unveil novel discoveries with significant ramifications for hematology. In addition to original research, HemaSphere features review articles and guideline articles that furnish lucid synopses and discussions of emerging developments, along with recommendations for patient care. Positioned as the foremost resource in hematology, HemaSphere augments its offerings with specialized sections like HemaTopics and HemaPolicy. These segments engender insightful dialogues covering a spectrum of hematology-related topics, including digestible summaries of pivotal articles, updates on new therapies, deliberations on European policy matters, and other noteworthy news items within the field. Steering the course of HemaSphere are Editor in Chief Jan Cools and Deputy Editor in Chief Claire Harrison, alongside the guidance of an esteemed Editorial Board comprising international luminaries in both research and clinical realms, each representing diverse areas of hematologic expertise.